iShares $ Corp Bond ETF USD Dist (LQDA)
| Previous close | 12.55 |
| Open | 12.50 |
| Bid | 12.19 x 200 |
| Ask | 12.31 x 100 |
| Day's range | 11.80 - 12.50 |
| 52-week range | 5.71 - 16.99 |
| Volume | |
| Avg. volume | 840,275 |
| Market cap | 929.926M |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference
MORRISVILLE, N.C., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, and Micheal Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, beginning at 1:30 p.m. Eastern Time. Access to a webcast will be availa
- GlobeNewswire
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
On March 28, Judge Andrews removed the injunction issued in the Original Hatch Waxman LitigationOn March 29, Judge Bates denied United Therapeutics’ motion for temporary restraining order and preliminary injunction in separate litigation filed by United Therapeutics against the FDAOn March 31, regulatory exclusivity expired for Tyvaso® in treating PH-ILD MORRISVILLE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that on Mar
- GlobeNewswire
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalidAdvancing industry leading portfolio for inhaled treprostinil with YUTREPIA and sustained-release program L606Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial
